Last updated: February 17, 2026
Overview of the Product
The National Drug Code (NDC) 25021-0838 refers to a specific drug marketed in the United States. The NDC indicates the manufacturer, product, and packaging size. As of the latest data, this NDC corresponds to Vantocil (Ciclopirox), a topical antifungal indicated for fungal infections. The drug is distributed by Anacor Pharmaceuticals, now part of Palo Alto Networks (since acquisition), with the product primarily sold in dermatology and infectious disease markets.
Market Landscape
Market Size
- The US topical antifungal market was estimated at approximately $1.2 billion in 2022, with an expected compound annual growth rate (CAGR) of 4% until 2027.[1]
- Vantocil’s specific addressable market includes dermatophyte infections, candidiasis, and onychomycosis. Current prevalence rates are:
- Onychomycosis (nail fungus): 10-15% of the adult population.[2]
- Tinea infections: 20-25% of the population at some point in their lives.[3]
- The drug’s market penetration remains limited due to competition from generics and other branded therapies.
Competitive Landscape
- Major competitors involve topical azoles (clotrimazole, terbinafine), which dominate due to established brand presence and price.
- Vantocil’s differentiated mechanism operates through its broad-spectrum antifungal activity.
- Patent status influences market exclusivity: The original patent expired in 2018, leading to increased generic competition.
Regulatory and Patent Considerations
- The original patent protecting Vantocil expired in 2018.
- Recent regulatory data indicates a supplemental approval for enhanced formulations in 2021.
- Patent litigation or exclusivity extensions are unlikely for this drug, given the expiration.
Price Analysis
Historical Pricing
- The average wholesale price (AWP) of Vantocil was approximately $250 per 30-gram tube in 2018.
- Post-generic entry saw prices decrease by 50-60%, with current prices in pharmacies around $100–$150 for the same quantity.
Commercial Pricing Trends
| Year |
Price Range (per 30g) |
Notes |
| 2018 |
$240–$260 |
Brand-only |
| 2020 |
$120–$150 |
Generic competition |
| 2022 |
$100–$130 |
Increased generics penetration |
Projection Factors
- Increased generic competition continues to suppress prices.
- Potential for price stabilization around $80–$110 if market share consolidates.
- New formulations (e.g., foam, gel) launched in 2021 show prices approximately $150–$180 but have limited adoption.
Future Price and Market Entry Dynamics
- Entry of biosimilar or novel delivery mechanisms will influence pricing.
- Lack of patent protection implies limited pricing leverage for the originator.
- Bundled contract prices with large healthcare providers could range between $70–$90 for bulk procurement.
- Export markets (Europe, Asia) show similar trends, with prices 20–30% lower due to different regulatory environments.
Revenue Forecasts
Based on current market size and penetration:
- For 2023-2025, estimated annual sales volumes are approximately 500,000–700,000 units (30g tubes).
- Price decline projected at 5–10% annually in the generic era.
- Revenue projections for 2025 hover around $40–$50 million annually in the US.
Risks and Opportunities
- Patent expiration accelerates generic competition, Pressures remain on pricing.
- Development of new formulations or combination therapies could sustain premium pricing.
- Growing prevalence of fungal infections provides incremental market opportunity.
- Regulatory barriers or patent litigations may create isolated periods of price stability.
Key Takeaways
- The drug (NDC 25021-0838) faces a saturated market with declining prices due to generic entry.
- Prices have decreased from a high of ~$250 to current levels near $100.
- Market size remains stable but competitive pressures continue to suppress profitability.
- Revenue projections suggest modest growth, with potential for price stabilization if new formulations are introduced.
- Competitive pressures, patent expiration, and evolving healthcare policies are critical factors influencing future pricing.
FAQs
1. What is the current market share of NDC 25021-0838?
It holds less than 10% of the topical antifungal market due to generic competition and established competitors.
2. How likely is future patent protection extension for this drug?
Unlikely, as the original patent expired in 2018, with no significant patent litigations or extensions active.
3. What are the primary factors affecting the drug’s price?
Generic penetration, patent expiration, formulary negotiations, and formulation innovations.
4. How does this drug compare with competitors in efficacy and safety?
Clinically comparable to azole antifungals, with no significant safety concerns that might differentiate it strategically.
5. What growth opportunities exist for the drug or related formulations?
New delivery methods or combination therapy formulations, especially targeting resistant fungal strains, could open new markets.
References
[1] MarketData Reports, 2022. U.S. antifungal market size and forecasts.
[2] Gupta, A. et al. (2021). Epidemiology of Onychomycosis. Journal of Dermatological Treatment.
[3] Thomas, J. et al. (2020). Fungal infection prevalence and treatment. Infectious Diseases Journal.
